Imaging cortisol metabolism in liver, adipose tissue and brain with a novel PET radioligand
- Study HIC#:2000029576
- Last Updated:02/22/2024
Obesity and fatty liver disease negatively impacts an individual’s health and quality of life, and affects a substantial burden on communities and society. The proposed research program will investigate the changes in cortisol metabolism during normal physiology, and during the progression to obesity and fatty liver disease in an attempt to understand the role of cortisol metabolism. A better understanding of cortisol metabolism, and particularly the relationship between an enzyme that activates cortisol and obesity and fatty liver, may inform more effective treatment strategies, improving quality of life and reducing societal burden.
Contact Us
For more information about this study, including how to volunteer, contact:
Mark Dias
- Phone Number: 1-203-737-6128
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
Obesity and fatty liver disease negatively impacts an individual’s health and quality of life, and affects a substantial burden on communities and society. The proposed research program will investigate the changes in cortisol metabolism during normal physiology, and during the progression to obesity and fatty liver disease in an attempt to understand the role of cortisol metabolism. A better understanding of cortisol metabolism, and particularly the relationship between an enzyme that activates cortisol and obesity and fatty liver, may inform more effective treatment strategies, improving quality of life and reducing societal burden.
Eligibility Criteria
Inclusion criteria:
Adults (age 18-85 years), will be recruited as either lean (BMI 18.5-24.9 kg/m2) or non-diabetic obese (BMI 30-60 kg/m2) or NASH (≥ stage 1; >5% hepatic triglyceride content) with a fasting plasma glucose (FPG) <126 mg/dL and a hemoglobin A1c <6.5%, to confirm non-diabetic status, and participants must be able to provide written and verbal informed consent.
